Literature DB >> 9920089

Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation.

M W Sullivan1, A Stewart-Akers, J S Krasnow, S L Berga, A J Zeleznik.   

Abstract

During the follicular phase of the menstrual cycle, FSH stimulates follicular growth, granulosa cell aromatase activity, induction of LH receptors on the granulosa cell membrane, and estradiol secretion. As a result of negative feedback of estradiol on the pituitary, serum FSH concentrations decline. Despite the fall in FSH concentrations, the maturing follicle continues to develop to the preovulatory stage. In a prospective randomized trial, we tested the hypothesis that a key mechanism by which the dominant follicle continues to develop in the face of decreasing concentration of FSH is by acquiring LH responsiveness. In 24 women, pituitary gonadotropin secretion was down-regulated with a GnRH agonist. Follicular growth was then stimulated with recombinant human FSH (r-hFSH) until a 14-mm follicle was identified by ultrasound. The women were then randomized to 1 of 4 groups for a 2-day period: continued r-hFSH treatment, substitution of r-hFSH with saline, low dose r-hLH (150 IU, twice daily), or high dose r-hLH (375 IU, twice daily). Serum estradiol concentrations in the women receiving saline declined by the end of the 2-day randomization period. In contrast, serum estradiol concentrations continued to rise in women receiving either r-hFSH or r-hLH compared with those in the saline-treated group (P < 0.05). Pregnancies occurred in each of the gonadotropin treatment groups. These findings indicate that once FSH initiates follicular growth, either FSH or LH is capable of sustaining follicular estradiol production. Extrapolating these findings to the normal menstrual cycle suggests that the maturing follicle may continue to develop in the presence of diminishing FSH concentrations by acquiring the capacity to respond to LH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920089     DOI: 10.1210/jcem.84.1.5389

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  The normal human menstrual cycle.

Authors:  N Chabbert-Buffet; P Bouchard
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Toxic effects of maternal zearalenone exposure on uterine capacity and fetal development in gestation rats.

Authors:  Yuanyuan Zhang; Zhiqiang Jia; Shutong Yin; Anshan Shan; Rui Gao; Zhe Qu; Min Liu; Shaoping Nie
Journal:  Reprod Sci       Date:  2013-12-19       Impact factor: 3.060

3.  Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.

Authors:  Kyono Koichi; Nakajo Yukiko; Kumagai Shima; Sasaki Sachiko
Journal:  J Assist Reprod Genet       Date:  2006-06-20       Impact factor: 3.412

4.  Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.

Authors:  Karen L Lee; Grace M Couchman; David K Walmer
Journal:  J Assist Reprod Genet       Date:  2005-01       Impact factor: 3.412

5.  Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.

Authors:  Barbara Sonntag; Ludwig Kiesel; Eberhard Nieschlag; Hermann M Behre
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

6.  Enough is enough! Patients who do not conceive on 600 IU/d of gonadotropins show no improvement from an additional 150 IU of LH activity.

Authors:  Marcy Maguire; John Csokmay; James Segars; Mark Payson; Alicia Armstrong
Journal:  Fertil Steril       Date:  2010-09-17       Impact factor: 7.329

Review 7.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

Review 8.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13

10.  "hCG priming" effect in controlled ovarian stimulation through a long protocol.

Authors:  Panagiotis Beretsos; George A Partsinevelos; Eleni Arabatzi; Peter Drakakis; Depy Mavrogianni; Elli Anagnostou; Kostas Stefanidis; Aris Antsaklis; Dimitris Loutradis
Journal:  Reprod Biol Endocrinol       Date:  2009-08-31       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.